Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 16:05 ET | Source: Ardelyx, Inc.

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
November 05, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
November 04, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
October 30, 2025 16:01 ET | Source: Ardelyx, Inc.

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to...
October 28, 2025 08:01 ET | Source: Ardelyx, Inc.

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for...
October 21, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week

WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
October 13, 2025 08:35 ET | Source: Ardelyx, Inc.

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
October 13, 2025 08:30 ET | Source: Ardelyx, Inc.

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
August 25, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
August 04, 2025 16:08 ET | Source: Ardelyx, Inc.

Ardelyx Announces Changes to the Executive Leadership Team

Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the...